COMMUNIQUÉS West-GlobeNewswire

Paul Chaplin Steps Down as CEO of Bavarian Nordic
02/03/2026
COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
02/03/2026
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing [...]
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
02/03/2026
Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug designation for [...]
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
02/03/2026
ZURICH, SWITZERLAND – March 2, 2026 -- VERAXA Biotech AG (“ VERAXA ”), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech [...]
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4
02/03/2026
Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 La désignation s’appuie sur les données positives d’une étude de phase 2 sur le rilzabrutinib dans la [...]
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
02/03/2026
BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor [...]
Investor Education Webinar
01/03/2026
The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join [...]
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
01/03/2026
-- - 18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 [...]
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
01/03/2026
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong [...]
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
01/03/2026
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an [...]
OrganTech Defines Minimal Stem Cell Set Enabling Functional Hair Follicle Regeneration In Vitro
01/03/2026
TOKYO, March 01, 2026 (GLOBE NEWSWIRE) -- OrganTech, Inc. announced that its research team has defined a minimal stem cell set required for functional hair follicle regeneration in vitro, establishing a defined cellular [...]
WriteUpp Automated Reminders and Smart Booking Tools Drive Double-Digit Reductions in Healthcare No Show Rates
01/03/2026
WriteUpp practice management platform combines automated SMS reminders and configurable booking rules to help healthcare providers recover lost revenue and keep appointment schedules full LONDON, Feb. 28, 2026 (GLOBE [...]
DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI
28/02/2026
Châtillon, France, le 28 février (20 :25 CET) 2026 DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI Environ 83 % des enfants traités avec [...]
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
28/02/2026
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut [...]
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
28/02/2026
Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms 99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with [...]
CUKTECH 25SE Power Bank Makes Its Powerful Debut in Malaysia, Setting a New Benchmark for High-Capacity Fast Charging
28/02/2026
KUALA LUMPUR, Malaysia, Feb. 28, 2026 (GLOBE NEWSWIRE) -- CUKTECH, a leading innovator in intelligent charging solutions, today announced the official launch of its highly anticipated CUKTECH 25SE Power Bank in the [...]
Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services
28/02/2026
BEIJING, Feb. 28, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has signed a strategic collaboration agreement with [...]
Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting
28/02/2026
Informational consumer guide examines Zealthy's online ED treatment model, sublingual Hardies formulations, provider evaluation process, subscription structure, and compounded medication disclosures for men evaluating [...]
Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment
28/02/2026
An informational consumer overview of Zealthy's prescription hydroquinone program, including compounded medication status, FDA context, telehealth dermatology consultation details, subscription and refund terms, side [...]

Pages